News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: CEL-SCI Corporation (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research provides an update on CEL-SCI Corporation, maintaining Buy rating with a revised target price of USD 15. The company's partnership with Amarox and upcoming clinical milestones are highlighted -
-
-
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Ad-hoc | IVU Traffic Technologies AG: Preliminary results for the first half of 2026 exceed expectations – full-year 2026 earnings guidance raised
IVU Traffic Technologies AG reports preliminary results for the first half of 2026 that exceed expectations, leading to a raised earnings guidance for the full-year 2026 -